Bio/Pharma IPOs in Q3 2026: More Deals, Bigger Checks

11 minutes ago

2 min read

Bio/pharma IPO activity increased in Q3 2026, with BPIQ recording 10 priced offerings, compared with seven in Q1 and eight in Q2. July brought three listings, August five, and September two. That puts 2026 at 25 IPOs through September, already above the full-year total for each year from 2022 through 2025.

The Quarterly View

Q3 was the busiest quarter since 2021 in BPIQ’s dataset. Still, its 10 IPOs were well below the 25 recorded in Q3 2021. Activity is recovering, but the market remains some distance from boom-era volumes (Fig. 1).

Fig. 1. Quarterly bio/pharma IPO activity and market cycle (2018 - Q3 2026).

The Monthly View

The quarter’s activity was uneven (Fig. 2): July recorded three IPOs, August five, and September two. August accounted for half of Q3’s listings and tied February as 2026’s busiest month. September’s slower pace suggests the reopening has yet to settle into a steady rhythm.

Fig. 2. Monthly bio/pharma IPO activity and market backdrop (2018 - Q3 2026).

Larger Offerings and Post-IPO Performance

Four Q3 offerings illustrate the scale of capital raised: ADARx ($446.3 million), Braveheart Bio ($382.5 million), Electra ($350 million), and Latigo ($345.6 million). Together, these offerings represented approximately $1.52 billion in gross proceeds at pricing, before underwriting fees and offering expenses and excluding subsequent exercises of underwriters’ options.

Across the year, BioPharma Dive counted 11 biotech IPOs above $300 million through September 17, matching its full-year 2021 tally [1]. All 11 companies had a drug in Phase 2 development or later. This describes the clinical maturity of the companies completing those larger offerings; it does not establish which characteristics drove investor demand.

Post-IPO performance provides another measure. In BioCentury’s separate cohort of 2026 Nasdaq biotech listings, 18 of 21 companies were trading above their offer prices as of September 1, with a median gain of 36% [2]. Those figures show gains across most of that cohort at the measurement date, rather than performance through the end of Q3.

Final Thoughts

The increase in IPO activity through Q3, alongside the rebound in private funding, is consistent with the sequence outlined in our earlier analysis: stronger public biotech markets followed by increased IPO issuance and, subsequently, higher private funding activity. The recovery has nevertheless been uneven, with private funding declining in Q2 before rebounding in Q3 and public biotech indices delivering divergent returns during the quarter. These developments support our earlier thesis, but do not yet establish whether the momentum will continue into Q4. Note: IPO counts use the BPIQ dataset through September 2026; counts from other trackers may differ by inclusion criteria.